Introduction: Self-therapy interventions could potentially reduce expenses and the need for care in the treatment of depression and anxiety disorders. The current study assessed the cost-effectiveness of Cognitive Self-Therapy (CST) in patients with depression and anxiety disorders. Method: 151 patients were randomly assigned to CST or treatment as usual (TAU), and prospectively followed during 18 months. The Symptom Checklist 90 (SCL-90) was the primary outcome measure in the cost-effectiveness analysis. Results: Mean costs of patients in the CST group (€4028) were lower than the mean costs of patients who received TAU (€4837). Results of the SCL-90 were slightly in favour of CST. Additional analyses indicated that CST dominated TAU in 50% of the bootstrap replications. Conclusion: Differences in health outcomes between CST and TAU were modest. Mean costs of patients in the CST group were €809 lower than in TAU. Valuing an additional unit of health outcome at €100 will lead to an 83% probability that CST is cost-effective.
Introduction
Many patients suffering from depression or anxiety disorders can not adequately be treated within current European healthcare systems (1) . The number of available therapists is limited and unable to meet the extensive need for care. Unfortunately, the consequences of inadequate treatment of mental illness can be serious, both for the well-being of patients as for national healthcare expenses, especially in case of recurring or chronic mental disorders (2, 3) . Various studies have indicated that self-help strategies can form an effective alternative for treatment provided by therapists, also in patients with depression or anxiety disorders (4) . Self-help strategies are currently provided to patients in various formats, including self-help manuals and computerised programmes. For policy makers, the potential cost savings associated with self-help strategies are particularly interesting. However, only a limited number of studies analysed both costs and health outcomes of self-help strategies aimed at emotional disorders, and the methodological quality of available studies has been questioned (5) . In one of the rare economic evaluations of self-help strategies in patients with depression and anxiety disorders (6) , the cost-effectiveness of computerised cognitive behavioural therapy (CBT) was examined. Based on costs and health outcomes registered during 8 months, the authors concluded that computerised CBT was likely to be cost-effective compared to treatment as usual. These findings underline the relevance of economic evaluations of self-help strategies in mental healthcare, and provide support for economic studies on other forms of self-help strategies as well. Recently, a randomised clinical trial (7) focused on Cognitive Self-Therapy (CST) in patients with depression and anxiety disorders. CST integrates self-help manuals and depression courses with support provided by paraprofessionals. There were prior indications of the effectiveness of CST (based on an unpublished pilot study), but no large trials had been conducted before.
Aims of the study This paper will present the results of the economic evaluation that was performed alongside the clinical trial on CST. The economic evaluation assessed the costeffectiveness of CST in comparison with treatment as usual (TAU) in patients with depression and anxiety disorders.
Material and Methods
The economic evaluation was part of an 18-month clinical study on the effectiveness of CST in patients with depression and anxiety disorders. Details on the design and results of the clinical study are provided elsewhere (7) .
Study population
Recruitment of patients took place between 2000 and 2002 in four outpatient centres located in different parts of the Netherlands. Patients were eligible for the study if they had a diagnosis of depression or generalised anxiety disorder. Additional selection criteria included a history of mental healthcare utilisation of at least two years, aged between 18 and 65, and an awareness of personal vulnerability in social contacts and/or relationships. Patients were excluded if they displayed suicidal behaviour or psychotic symptoms, had a comorbid diagnosis within the autistic spectrum or an organic disorder, were drug or alcohol dependent, or mentally handicapped (IQ<85).
Randomisation procedure and interventions
Stratified randomisation was applied to ensure the comparability of patient groups. Strata were based on age; <40 years of age or >=40 years of age, and duration of complaints; <7 years or >= 7 years. Patients were randomly assigned to two intervention arms, CST or treatment as usual (TAU). Both interventions were provided in outpatient centres and included a first contact for diagnostic purposes. During the study, patients received any form of regular care they required in addition to the care that was part of the interventions. TAU in the Netherlands consisted of 10-20 contacts with a psychologist, psychiatric nurse or social worker. During these contacts, healthcare professionals mainly focused on problem solving and coping strategies, but they did not follow a prescribed treatment protocol. CST is a method developed to restructure cognitive schemata and address problems in social functioning and relationships. Psychiatric nurses, social workers and psychologists can be trained to perform CST programmes and to teach the CST method to patients. Patients use a CST manual (8) that acquaints them with the treatment principles. The patients' role in the treatment gradually evolves into that of a "paraprofessional", such that they finally conduct CST sessions in reciprocal relationships with peers. The CST programme consists of: a) Preparatory phase of one to three 45 minute meetings, for informing the patient and for checking whether the patient is able and willing to participate in the CST course; b) Orientation course of three mornings, once a week, during which the patients practice with peers, before definitely making the choice to continue with the next phase; c) Basic course of 5 days, once a week, in which patients learn to manage a CST session. Those who perform a CST session adequately with peers will become certified to participate in the last phase of the CST programme: d) Self-Therapy meetings, once a week, led by peers in accordance with the manual as was taught during the basic course. All certified patients had the free choice of participating in Self-Therapy meetings whenever they liked and could attend these meetings during the study period. Before the beginning of the study, the CST programme was uniformly implemented in all participating centres.
Outcome measures and power analysis
The Symptom Checklist 90 (SCL-90; 9) was the main outcome measure of the study. The SCL-90 is a multi-dimensional self-report inventory that can identify psychological problems and symptoms of psychopathology. The total score of the SCL-90 is based on nine subscales and can range from 90 -450, where lower scores indicate better functioning. Power analyses were based on characteristics of this instrument in the patient population under study; 61 patients were required in each treatment condition in order to detect a clinically relevant difference of 23 points between groups (SD=50) with an alpha of .05 and a power of 80%. In total 151 patients were included in the study to account for an estimated drop-out rate of 20%. Measurement took place at six-month intervals, starting at the time of inclusion until the end of the follow-up period 18 months later (T0, T6, T12, T18). Various additional instruments were administered during the clinical study, focusing on depressive symptoms (Beck Depression Inventory; 10), social anxiety (State-Trait Anxiety Inventory; 11), social functioning (Groningen Social Disabilities Schedule; 12) and quality of life (World Health Organization Quality of Life Assessment-BREF; 13). Results of these additional instruments could not directly be included in the economic evaluation due to the theoretical framework of cost-effectiveness analysis, which requires the inclusion of a single outcome.
Costs and unit prices
The economic evaluation was conducted from a societal perspective, therefore costs were assessed both within and outside the healthcare sector. Table 1 shows the various types of costs that were registered during the 18 months of the study. Costs of CST included costs of therapists who were training, educating and supporting patients during the various stages of the CST programme. Costs of travelling and invested time related to the CST meetings were registered during the study. Costs of invested time were valued in monetary terms based on the net income of patients. Costs of informal care were based on the monetary valuation of the time invested by relatives or acquaintances in helping or assisting the patient. Additional costs related to the illness, like costs of non-prescribed medication, are combined under the heading out-of-pocket costs. The friction cost method (14, 15) was applied for estimating costs associated with productivity losses. When applying the friction cost method, production losses are assumed to be confined to the period needed to replace the sick worker (currently estimated at five months in the Netherlands).
Quantities of used resources were registered for all the patients available at the various times of measurement. The information on costs was primarily collected by means of a questionnaire previously used in economic evaluations in mental healthcare (16) . This questionnaire assessed, among others, number of admissions to psychiatric hospitals, contacts with psychiatrists and psychologists, and sick leave days of patients. Additional information, like medication use, was collected through various healthcare professionals. In order to facilitate comparisons with other economic evaluations, unit prices, i.e. the price of one unit of each included cost type (available on request), were mainly based on Dutch standard prices (17) . True costs of used resources were estimated when standard prices were not available. All unit prices were based on the price level of the Euro in the year 2003. Reference prices established for previous years were adjusted to prices of 2003 by applying the consumer price index.
Cost-effectiveness analysis
In cost-effectiveness analysis, costs and the primary health outcome associated with an intervention are used to calculate the incremental cost-effectiveness ratio relative to one or more alternatives (18) . In the present study, costs and health outcomes of patients who received CST were compared with those of patients in the TAU condition. Primary outcome measure in the cost-effectiveness analysis was the SCL-90, the instrument on which power analyses of the clinical study were based. Costs per point improvement on the SCL-90 were expressed by the incremental cost-effectiveness ratio (ICER):
Where C CST = mean costs per patient in the CST group, C TAU = mean costs per patient in the TAU group, SCL90 CST = mean SCL-90 difference score in the CST group, SCL90 TAU = mean SCL-90 difference score in the TAU group.
In the standard analyses costs and health outcomes were not discounted. Discounting would have had a minor influence on differences between groups in the present study of 18 months (discounting will be addressed in the sensitivity analyses). Uncertainty surrounding the calculated ICER was examined by the bootstrap method (19) . Bootstrapping is an iterative method that consists of randomly selecting patient data (with replacement) from the observed population to create a simulated distribution of data. ICERs were calculated for each of the bootstrap iterations (5000 in the present study), simulated values of the mean estimates for the cost and outcome differences were added to the cost-effectiveness plane (20) . Finally, cost-effectiveness acceptability curves (CEACs) (21, 22) were calculated. CEACs inform decision-makers on the probability that an intervention will be cost-effective for increasing monetary values placed on an additional unit of health outcome.
Sensitivity analysis
Various sensitivity analyses were performed in order to provide information on the robustness of the results of the economic evaluation. Discount rates were varied (4% and 5% instead of 0%) and consequences for differences between groups were examined. Costs of hospital admissions are known to have a large impact on total costs in mental healthcare. In order to examine the uncertainty of this cost aspect in the current study, costs of hospital admissions were increased with 20% in one of the intervention arms, while at the same time being decreased with 20% in the other. Subsequently, consequences for differences in total costs between groups were analysed. Additional sensitivity analyses focused on the exclusion of costs related to productivity losses.
Statistical analysis
Analyses of costs and clinical outcomes were conducted on an 'intention-to-treat' basis, using mixed models under the assumption of missingness at random. Mixed models is a repeated measurement analysis that uses all available data, i.e. also of patients for whom one or more measurements are missing. The applied models included main effects of treatment condition and assessment time and their interaction, with a random effect of subject. The baseline score of the SCL-90 was included to account for initial differences between groups. Between-group baseline characteristics were analysed with Student's T-tests for continuous variables and Pearson chi-square tests for categorical variables. Pvalues less than 0.05 were considered statistically significant. All the analyses were carried out with SPSS 12.0.2 for Windows (SPSS, Inc, Illinois, USA).
Results

Patient characteristics at baseline
The CST group consisted of 52 women (69%) and 23 men (31%) with a mean age of 40.7 years (SD=8.9). In the TAU group there were 48 women (63%) and 28 men (37%) with a mean age of 41.9 years (SD=9.1). Main diagnoses in both groups were depressive disorder (91% in CST, 97% in TAU) and generalised anxiety disorder (9% in CST, 3% in TAU). More than half of the patients (52%) had a comorbid diagnosis of a depressive or anxiety disorder. The number of years since first contact with mental healthcare was 12.2 years (SD = 7.6) in the CST group and 13.1 years (SD = 9.0) in the TAU group. There were no statistically significant differences between groups on demographic (gender, age, living situation, level of education) or clinical characteristics (primary diagnosis, co-morbidity, time of first psychiatric contact, family psychiatric history) at baseline. Table 2 shows information on medical and non-medical cost, as well as service use. Means of each cost type are based on all patients in both groups. If a patient did not make use of a specific cost type, costs of €0 were applied when calculating group means. In addition, mean costs and number of patients who actually used the health services are presented as well. Total costs (medical and non-medical) of providing the CST intervention were estimated at €760 per patient. These costs consisted of costs of teaching CST to patients (€323), as well as travel and time costs of patients directly related to the CST meetings (€437). Costs of psychiatric hospital admissions, medication use and 'other out-patient care' contributed substantially to total medical costs in both groups. 'Other out-patient care' consisted of various types of treatment, including group therapy and social skills training. Travel costs and costs of invested time were only assessed when directly related to the CST intervention. Costs related to productivity losses, with and without absence from work, were relatively high in both groups. An overview of total costs during each measurement period and total costs during the 18 months of the study is presented in Table 3 . The costs of teaching CST to patients in the CST condition were generated during T0-T6, while the costs of attending peer meetings mainly took place during the following periods. During T6-T12, mean total costs in the CST group were lower, partially related to a decreased use of healthcare services. In the last six months of the study, total costs slowly increased again for patients in the CST group. For patients in the TAU group, there was somewhat less variation in total costs during the study. Mean total costs during the entire study period were €4028 per patient in the CST group (median costs €2255) and €4837 per patient in the TAU group (median costs €2511). Differences in mean total costs per measurement between groups were examined by 95% confidence intervals (CI) generated by the bootstrap method, in addition to the longitudinal analyses with mixed models. Differences in mean total costs during the 18 months of the study were not statistically significant (95% CI lower boundary: -€3693; upper boundary: +€1460) for patients for whom all the measurements were available. Results of the mixed model analyses on costs during T0-T18 are displayed in Table 4 . In the mixed model analyses, a significant effect of time was found; i.e. differences were found between costs over time for both groups. However, there was no significant treatment effect, nor was there a significant effect of the interaction between treatment and time. The fact that no significant differences between groups were found for costs should be interpreted with some caution, since the study was powered (as most economic evaluations) to demonstrate differences in health outcomes and not costs.
Service use and costs
Primary health outcome
Results of the SCL-90, the primary health outcome measure, are displayed in Table  5 . In the mixed model analyses (Table 4) , baseline SCL-90 scores were included as covariate due to the initial differences on this outcome measure between groups. 
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The effect of time was significant (later assessments showed lower scores in both groups), but there was no significant difference between treatments, nor a significant effect of the interaction between treatment and time.
Cost-effectiveness analysis
The point estimate of the ICER and the results of the bootstrap analyses are presented in the cost-effectiveness plane (CEP) in Figure 1 . The calculated value of the ICER was -€144 per point improvement on the SCL-90. Here, the negative value indicates that CST was associated with lower mean costs and better health outcomes. For each quadrant of the CEP, information is provided on the percentage of bootstrap simulations located in that quadrant. Approximately 50% of the estimated mean cost and effect differences is located in the southeast quadrant. In other words, CST dominates TAU in 50% of the cases. Interpretation of outcomes in the northeast and southwest quadrants depends on how much decision-makers are willing to pay for an additional unit of health outcome. Figure 2 shows the probability that CST will be cost-effective for increasing monetary values placed on an additional unit of health outcome. When decision-makers are willing to pay €100 per point improvement on the SCL-90, the probability that CST will be cost-effective increases up to 83%, and subsequently decreases. This decrease is due to the location of the joint density in the north-east and south-west quadrants of the cost-effectiveness plane (21) . Monetary valuation of an additional unit of health outcome (€) Probability that CST will be cost-effective
Sensitivity analyses
In the first type of sensitivity analysis, discount rates were varied and consequences for differences in mean total costs between groups were studied. Costs were discounted at 4% and 5%, instead of 0% in the standard analyses. Differences in mean total costs between groups were slightly smaller, i.e. €787 (4%) and €781 (5%) instead of €809 (0%) in favour of CST in the standard analyses. Other sensitivity analyses focused on variations in costs of hospital admissions, a cost category that may contribute considerably to the total amount of costs in mental healthcare (24% of total costs in current study). First, these costs were increased with 20% in the CST group, while at the same time being decreased with 20% in the TAU group. Subsequently, hospital costs were decreased by 20% in CST and increased in the TAU condition. The consequences of these variations for differences in mean total costs between groups were examined. Confidence intervals estimated by the bootstrap method indicated that mean cost differences between groups (€366 and €1253 in favour of CST, respectively) were not significant. Additional sensitivity analyses focused on productivity losses. When excluding costs of productivity losses, mean total costs were €2461 in the CST group and €3516 in the TAU group. In this alternative analysis, differences in mean total costs between groups (€1055) are more pronounced than in the standard analyses (€809).
Discussion
The current paper presented the results of the cost-effectiveness analysis that was part of an 18-month clinical study focusing on CST in patients with depression and anxiety disorders. A comparison was made between costs and health outcomes of patients who were randomly assigned to one of two treatment arms, CST or TAU. Overall results indicated that there were modest differences in health outcomes between CST and TAU. Furthermore, mean total costs of patients in the CST group were €809 lower than the costs of patients in TAU. Cost types that contributed considerably to the total amount of costs were related to hospital admissions, medication use, and 'other out-patient care'. Furthermore, costs of productivity losses with or without absence from work were relatively high, which is in line with the results of previous studies examining (societal) costs of patients with depression or anxiety disorders (23, 24) . The costs of training therapists in CST were not included in the current study. However, training costs will be relevant for decision-makers when considering the implementation of CST in current healthcare systems. The primary outcome measure of the cost-effectiveness analysis was the SCL-90. Differences between groups on the SCL-90 were much smaller than the assumed clinically relevant difference on which power analyses during the design phase of the study were based. The various instruments administered in addition to the SCL-90 showed results comparable with the primary outcome measure (7) . The overall outcomes of these instruments, which measured depressive symptoms, social anxiety, social functioning and quality of life, demonstrated that there were no statistically significant differences between groups on these aspects of health. As indicated by a recent literature overview (4), self-help strategies are commonly associated with results that seem comparable to those of other treatments. Therefore, it may be more appropriate to design studies on self-help strategies, including economic evaluations, as non-inferiority studies instead of superiority trials. Non-inferiority studies intend to show that an intervention is at least equal to an alternative in terms of effectiveness (25) . Non-inferiority designs can be applied when there are other advantages to be gained from an intervention than strictly improving effectiveness compared to other interventions. For instance, when an intervention leads to a decrease in healthcare utilisation and lower related healthcare costs, as seems to be the case for self-help strategies. Results of longitudinal studies can be biased by missing data due to patients who drop out or are lost to follow-up (26) . Recently, the potential impact of missing data has also been acknowledged in the area of economic evaluation (27) . In the current study, mixed models were used for longitudinal analyses of costs and health outcomes to deal with missing data. In the mixed model analyses, baseline results of the SCL-90 were included as covariate to correct for initial differences between groups. Cost-effectiveness acceptability curves were assessed to estimate the probability that CST will be cost-effective for increasing monetary valuations per unit of health outcome gained, which is considered to be relevant information for decisionmakers. Unfortunately, there is currently no (inter)national consensus on acceptable benchmarks for an additional unit of health outcome, neither for generic outcomes as the QALY (Quality-Adjusted Life Years) nor for more specific outcomes like the SCL-90 applied in the current study. Decision-makers will therefore have to interpret whether the indicated costs per additional unit of health outcome seem to be acceptable or not. Comparing the overall outcomes of the current cost-effectiveness analysis with other economic studies on self-help treatments is complicated because of the limited follow-up period of published studies. The time horizon of available studies typically ranges from 3 to 8 months (5, 6) . Conclusions based on such short study periods should be interpreted with some caution. Especially since initial positive consequences of psychiatric interventions may diminish over time (28) . In the present study, costs of patients in the CST condition slowly increased again in the last six months of the study, after a drop in service use during the previous measurement period. In order to adequately inform decision-makers, study periods of at least 12 to 18 months seem essential for economic studies in the field of mental healthcare. While the advantages of self-help strategies seem obvious, results of available economic studies do not always unambiguously confirm its potential benefits for the healthcare system in general, or healthcare expenses in particular. In terms of health outcomes, self-help strategies generally appear to be comparable with treatment provided by therapists. Current results indicated that CST in patients with depression and anxiety disorders will reduce societal costs, and is associated with somewhat better health outcomes than TAU. Valuing an additional unit of health outcome at €100 will lead to an 83% probability that CST is cost-effective. Consequently, CST could be applied to relieve the burden of many patients with depression or anxiety disorders who currently do not receive the necessary care due to a limited number of available therapists. Future economic studies focusing on self-help strategies (for instance in patients with a first episode of depression) may profit from the suggestions made in the present paper, including the use of a noninferiority design and a follow-up period of at least 12 to 18 months.
